Viatris (VTRS) Non-Current Debt (2019 - 2026)
Viatris' (VTRS) quarterly Non-Current Debt came in at $12.4 billion in Q1 2026, down 12.44% year-on-year from $14.2 billion in Q1 2025, and down 0.54% quarter-over-quarter from $12.5 billion in Q4 2025.
Viatris (VTRS) Non-Current Debt (2019 - 2026) Analysis & Trends
Viatris' Non-Current Debt history runs 8 years deep, the most recent figure standing at $12.4 billion for Q1 2026.
- On a quarterly basis, Non-Current Debt fell 12.44% year-over-year to $12.4 billion in Q1 2026; TTM through Mar 2026 was $12.4 billion, a 12.44% decrease from a year earlier, with the FY2025 full-year figure at $12.5 billion, down 11.1% from the prior year.
- Non-Current Debt retreated to $12.4 billion in Q1 2026 per VTRS's latest filing, from $12.5 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $19.2 billion in Q2 2022 and bottomed at $12.4 billion in Q1 2026.
- The 5-year median for Non-Current Debt is $16.1 billion (2024), against an average of $15.7 billion.
- Across the five-year window, Non-Current Debt fell 3.69% in 2023 and decreased 16.24% in 2024, its largest moves.
- Year by year, Non-Current Debt stood at $18.0 billion in 2022, then fell by 10.14% to $16.2 billion in 2023, then dropped by 13.28% to $14.0 billion in 2024, then declined by 11.1% to $12.5 billion in 2025, then decreased by 0.54% to $12.4 billion in 2026.
- Per Business Quant, the three latest VTRS Non-Current Debt figures stand at $12.4 billion (Q1 2026), $12.5 billion (Q4 2025), and $12.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 197.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.41 Bn |
| Dec 31, 2025 | 12.48 Bn |
| Sep 30, 2025 | 12.49 Bn |
| Jun 30, 2025 | 12.79 Bn |
| Mar 31, 2025 | 14.18 Bn |
| Dec 31, 2024 | 14.04 Bn |
| Sep 30, 2024 | 14.30 Bn |
| Jun 30, 2024 | 14.73 Bn |
| Mar 31, 2024 | 16.07 Bn |
| Dec 31, 2023 | 16.19 Bn |
| Sep 30, 2023 | 17.08 Bn |
| Jun 30, 2023 | 17.25 Bn |
| Mar 31, 2023 | 18.07 Bn |
| Dec 31, 2022 | 18.02 Bn |
| Sep 30, 2022 | 18.72 Bn |
| Jun 30, 2022 | 19.21 Bn |
| Mar 31, 2022 | 18.76 Bn |
| Dec 31, 2021 | 19.72 Bn |
| Sep 30, 2021 | 19.85 Bn |
| Jun 30, 2021 | 20.92 Bn |